{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:55:48Z","timestamp":1792454148483,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["821283-2"],"award-info":[{"award-number":["821283-2"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013865","name":"Stiftung Charit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["259373024"],"award-info":[{"award-number":["259373024"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.isci.2025.112383","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:17:23Z","timestamp":1744129043000},"page":"112383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics"],"prefix":"10.1016","volume":"28","author":[{"given":"Meng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Fern\u00e1ndez Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Dehlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardina","family":"Gallaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Diekmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Niederschweiberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"K\u00f6rtv\u00e9lyessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chotima","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.112383_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.isci.2025.112383_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14712598.2019.1568407","article-title":"B cell depletion in the treatment of multiple sclerosis","volume":"19","author":"Myhr","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.isci.2025.112383_bib4","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2025.112383_bib5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.isci.2025.112383_bib6","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \"enigma\" of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2025.112383_bib7","doi-asserted-by":"crossref","first-page":"25690","DOI":"10.1073\/pnas.2012249117","article-title":"B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis","volume":"117","author":"Nissimov","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.112383_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200084","article-title":"Ocrelizumab impairs the phenotype and function of memory CD8+ T cells: A 1-Year longitudinal study in patients with multiple sclerosis","volume":"10","author":"Mathias","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.isci.2025.112383_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207291120","article-title":"Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity","volume":"120","author":"Shinoda","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.112383_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200091","article-title":"Immune profiling reveals the T-cell effect of ocrelizumab in early relapsing-remitting multiple sclerosis","volume":"10","author":"Garcia","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.isci.2025.112383_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.109894","article-title":"Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab","volume":"259","author":"Beckers","year":"2024","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169584","article-title":"Ancestry-based differences in the immune phenotype are associated with lupus activity","volume":"8","author":"Slight-Webb","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2025.112383_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2025.112383_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fimmu.2018.00486","article-title":"CD161 defines a functionally distinct subset of pro-inflammatory natural killer cells","volume":"9","author":"Kurioka","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2011.04.008","article-title":"CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function","volume":"236","author":"Forde","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.isci.2025.112383_bib16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/1744666X.2021.1847642","article-title":"The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review. (2020)","volume":"16","author":"Ruprecht","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.112383_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy","volume":"22","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2025.112383_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103678","article-title":"The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: A hypothesis","volume":"59","author":"Berger","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.isci.2025.112383_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.isci.2025.112383_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217341","article-title":"Functions of double-negative B cells in autoimmune diseases, infections, and cancers","volume":"15","author":"Chung","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.isci.2025.112383_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.imlet.2023.03.003","article-title":"IgD-CD27- double negative (DN) B cells: Origins and functions in health and disease","volume":"255","author":"Beckers","year":"2023","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.isci.2025.112383_bib23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/febs.14292","article-title":"Nonapoptotic functions of Fas\/CD95 in the immune response","volume":"285","author":"Gu\u00e9gan","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.isci.2025.112383_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1009668212375","article-title":"CD95\/CD95L interactions and their role in autoimmunity","volume":"5","author":"Ricci-Vitiani","year":"2000","journal-title":"Apoptosis"},{"key":"10.1016\/j.isci.2025.112383_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fimmu.2012.00207","article-title":"The Fas\/CD95 Receptor Regulates the Death of Autoreactive B Cells and the Selection of Antigen-Specific B Cells","volume":"3","author":"Koncz","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2025.112383_bib27","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V96.10.3522","article-title":"Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells","volume":"96","author":"Richards","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.112383_bib28","doi-asserted-by":"crossref","first-page":"E546","DOI":"10.1073\/pnas.1416276112","article-title":"Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions","volume":"112","author":"Seifert","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.112383_bib29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4049\/jimmunol.182.2.890","article-title":"Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells","volume":"182","author":"Good","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.isci.2025.112383_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.isci.2025.112383_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200083","article-title":"Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis","volume":"10","author":"Ho","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.isci.2025.112383_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/cmi.2010.82","article-title":"4-1BB signaling beyond T cells","volume":"8","author":"Vinay","year":"2011","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib34","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/biomedicines10092099","article-title":"The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy","volume":"10","author":"Pachner","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2025.112383_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200268","article-title":"Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion","volume":"11","author":"Gawde","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.isci.2025.112383_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104465","article-title":"Selective emergence of antibody-secreting cells in the multiple sclerosis brain","volume":"89","author":"Bogers","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2025.112383_bib37","doi-asserted-by":"crossref","first-page":"32478","DOI":"10.1074\/jbc.274.45.32478","article-title":"Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors","volume":"274","author":"Proudfoot","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.112383_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51311-9","article-title":"Dendritic cells and regulatory T cells expressing CCR4 provide resistance to coxsackievirus B5-induced pancreatitis","volume":"9","author":"Fran\u00e7ozo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.112383_bib39","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1073\/pnas.1114153109","article-title":"CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells","volume":"109","author":"Poppensieker","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.112383_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106314","article-title":"The role of chemokines and chemokine receptors in multiple sclerosis","volume":"83","author":"Cui","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.isci.2025.112383_bib41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2019.01147","article-title":"The CD14+HLA-DRlo\/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy","volume":"10","author":"Mengos","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/ar2590","article-title":"Increased expression of FcgammaRI\/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus","volume":"11","author":"Li","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.isci.2025.112383_bib43","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1038\/s41467-023-43553-z","article-title":"Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.112383_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841687","article-title":"New Insights of CCR7 Signaling in Dendritic Cell Migration and Inflammatory Diseases","volume":"13","author":"Hong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.112383_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-7771-2-1","article-title":"Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases","volume":"2","author":"Yang","year":"2014","journal-title":"Biomark. Res."},{"key":"10.1016\/j.isci.2025.112383_bib46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri2297","article-title":"CCR7 and its ligands: balancing immunity and tolerance","volume":"8","author":"F\u00f6rster","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib47","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ana.20049","article-title":"Expression of CCR7 in multiple sclerosis: implications for CNS immunity","volume":"55","author":"Kivis\u00e4kk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.isci.2025.112383_bib48","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.0902542","article-title":"IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9","volume":"184","author":"Yen","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2025.112383_bib50","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s40001-023-01375-1","article-title":"Serum neurofilament light chain in COVID-19 and the influence of renal function","volume":"28","author":"K\u00f6rtvelyessy","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.isci.2025.112383_bib51","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1038\/s41467-022-34719-2","article-title":"Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer's disease","volume":"13","author":"Fern\u00e1ndez Zapata","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.112383_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55852-x","article-title":"Multi-parameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass cytometry in patients with early multiple sclerosis","volume":"9","author":"B\u00f6ttcher","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.112383_bib53","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cels.2018.02.010","article-title":"Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry","volume":"6","author":"Chevrier","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.isci.2025.112383_bib54","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3389\/fimmu.2019.02367","article-title":"Minimizing Batch Effects in Mass Cytometry Data","volume":"10","author":"Schuyler","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.112383_bib55","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.isci.2025.112383_bib56","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry. A."},{"key":"10.1016\/j.isci.2025.112383_bib57","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2025.112383_bib58","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","article-title":"NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","volume":"14","author":"Feng","year":"2023","journal-title":"Nat. Commun."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225006443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225006443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:22:50Z","timestamp":1778901770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225006443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2589004225006443"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.112383","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.112383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112383"}}